CXCR1: Function, Signaling, and Role in Disease

CXCR1 is a receptor protein embedded in the surface of immune cells, most prominently neutrophils, where it detects the chemical signal interleukin-8 (also called CXCL8) and triggers cells to move toward sites of infection or tissue damage. It belongs to the G-protein-coupled receptor (GPCR) superfamily, which is the largest family of signaling receptors in the human body and a major target for drug development.¹ Because CXCR1 sits at the intersection of immune defense, chronic inflammation, and cancer biology, understanding how it works has become increasingly relevant to researchers hunting for new therapies.

How CXCR1 Is Built and How It Recognizes Its Ligand

CXCR1 is a class A, rhodopsin-like GPCR, meaning it shares its basic architecture with the light-sensing protein in your eyes: seven columns of protein that thread back and forth through the cell membrane, with loops dangling on either side. The outer loops and the receptor’s tail interact with the signaling molecule (the chemokine CXCL8), while the inner loops interact with signaling proteins inside the cell.² Two small bridges made of sulfur-containing amino acids, called disulfide bonds, hold the outer structure together: one links the receptor’s tail to the top of the seventh transmembrane column, and the other pins the third column to an extracellular loop.³

When CXCL8 arrives, binding happens in two steps across two contact regions. First, the receptor’s flexible tail threads into a groove on the CXCL8 molecule, forming a docking site researchers call CRS1 that involves both electrical and physical contacts. Then, the tail-end of CXCL8 plunges into a pocket formed between the receptor’s transmembrane columns (CRS2), reaching deep enough to interact with specific residues on the second and seventh helices. This two-site handshake locks the chemokine in place and triggers the shape change inside the receptor that starts signaling.³

Why CXCR1 Is Picky About Which Form of CXCL8 It Binds

CXCL8 exists in the body as either a single molecule (monomer) or a pair stuck together (dimer). CXCR1 strongly prefers the monomer. In lab assays, an engineered locked dimer of CXCL8 needed roughly 85-fold higher concentrations than wild-type CXCL8, and about 32-fold more than a locked monomer, to activate CXCR1.⁴ The closely related receptor CXCR2, by contrast, responds more readily to both forms. The difference comes down to one specific extracellular loop: when researchers swapped that loop from CXCR2 into CXCR1, the chimeric receptor started responding to monomers and dimers in a pattern matching CXCR2.⁴

This monomer preference matters because the ratio of CXCL8 monomers to dimers shifts depending on local concentration. At sites of acute infection, where CXCL8 levels soar, dimers predominate. In surrounding tissue with lower concentrations, monomers are more common. CXCR1’s selectivity for monomers may therefore help fine-tune where and when neutrophils respond.

What Happens Inside the Cell After CXCR1 Is Activated

Once CXCL8 binds and the receptor changes shape, the inner portion of CXCR1 activates a G protein. Specifically, the sixth transmembrane helix swings outward, opening a cavity where the G protein’s signaling subunit can dock. Two residues deep within the receptor play distinct roles in this process. One residue on the third helix (Leu128) is essential for coupling to the G protein but has no effect on whether CXCL8 can bind: mutating it destroys signaling without blocking chemokine attachment. A different residue on the sixth helix (Val247) acts like a molecular safety latch, keeping the receptor in its off-state until a chemokine arrives. Replacing it with certain other amino acids removes that restraint and makes the receptor fire continuously, even without any CXCL8 present.⁵

CXCR1 also shows a built-in preference for one type of internal signal over another. When high-affinity chemokines bind, the receptor preferentially activates G proteins rather than recruiting β-arrestin, a molecule that would normally pull the receptor off the cell surface and shut it down. This “G protein bias” means that CXCR1 tends to keep signaling rather than being quickly silenced after it fires.⁶

How CXCR1 Gets Switched Off

After a receptor fires, the cell needs a way to dial it back down, or the immune response would run unchecked. For CXCR1, the primary off-switch involves a specific enzyme called GRK2. When GRK2 is removed from cells in the lab, CXCR1 becomes dramatically resistant to desensitization: only about 10 percent of receptors shut down compared with roughly 63 percent in normal cells. Interestingly, CXCR2 relies on a different enzyme, GRK6, for the same job.⁷ This difference is significant because it means the two receptors, despite sharing the same main chemokine, are regulated through separate molecular machinery. Drugs or genetic conditions that impair GRK2 could leave CXCR1 chronically active while barely touching CXCR2, and vice versa.

CXCR1 and Neutrophil Recruitment

The most well-established job of CXCR1 is guiding neutrophils, the immune system’s rapid-response cells, toward damaged or infected tissue. Work in zebrafish larvae with Cxcr1 genetically deleted showed that neutrophil recruitment to wound sites was severely impaired. Neutrophils in these animals could still move at normal speeds and with normal directionality in random migration, but they failed to navigate toward the wound. This pointed to a specific defect in directed migration rather than a general movement problem.⁸

The same study revealed that CXCR1 and CXCR2 handle opposing directions of neutrophil travel. While CXCR1 drives forward migration toward the wound, the reverse migration of neutrophils away from the wound once the crisis is over appears to depend on CXCR2 rather than CXCR1.⁸ Meanwhile, separate work on neutrophil behavior in microfluidic gradients of CXCL8 has demonstrated that at high absolute concentrations, neutrophils can actually reverse direction, moving away from the signal in a process called chemorepulsion. That reversal depends on CXCR2 rather than CXCR1.⁹ Together, the two receptors form a kind of bidirectional steering system: CXCR1 calls neutrophils in, and CXCR2 helps them leave once the job is done.

CXCR1 in Cancer Stem Cells

Beyond its role in normal immunity, CXCR1 has attracted considerable attention in cancer biology, where it marks and sustains cancer stem cells (CSCs). These are the small subpopulation of tumor cells thought to drive regrowth after treatment and seed metastasis. CXCR1 has been identified as a CSC marker in several solid tumor types.¹⁰

In breast cancer, blocking CXCR1 with either a specific antibody or a small-molecule inhibitor called repertaxin selectively depleted the cancer stem cell population in lab models. What happened next was striking: the death of these stem cells triggered a wave of cell death in the bulk tumor population through a signaling cascade involving the FAS pathway. In mouse xenograft experiments, repertaxin slowed tumor growth and reduced the spread of cancer to other organs.¹¹

Pancreatic cancer tells a similar story. Treating pancreatic cancer cells with CXCL8 in the lab more than doubled the proportion of cells showing the stem-cell-associated surface markers CD44 and CD24, and blocking the CXCL8-CXCR1 connection with an antibody reversed that effect. CXCL8 also enhanced the cells’ ability to form mammospheres, a lab proxy for stem-like self-renewal capacity, and blocking CXCR1 abolished that ability as well.¹²

Shaping the Tumor Microenvironment

CXCR1 and CXCR2 also influence the broader neighborhood around a tumor. The CXCL8 that tumors release does more than sustain cancer stem cells. It recruits immunosuppressive cells that dampen the body’s anti-tumor immune response, promotes the growth of new blood vessels that feed the tumor (angiogenesis), and encourages cancer cells to adopt a more mobile, invasive form through a process called epithelial-to-mesenchymal transition.¹³ These effects make the CXCL8-CXCR1/2 axis a tempting drug target, particularly in combination with immunotherapy, where removing the immunosuppressive brake might allow checkpoint inhibitors to work more effectively.

Inflammatory Disease Beyond Cancer

Because CXCR1 is fundamentally a neutrophil guidance receptor, it shows up wherever excessive neutrophil infiltration causes harm. In acute respiratory distress syndrome (ARDS), massive neutrophil influx into the lungs damages tissue and worsens outcomes. Mice engineered to lack CXCR1 or CXCR2 are protected against acute lung injury triggered by bacterial toxins or high-oxygen exposure.¹⁴ This finding positions CXCR1 blockade as a potential way to limit lung damage during ARDS without eliminating the immune system entirely.

Inflammatory bowel disease (IBD) offers a more nuanced picture. In Crohn’s disease, peripheral blood immune cells produce significantly less CXCL8 when stimulated compared to cells from healthy individuals or from patients with ulcerative colitis. That reduced production was specific to CXCL8 and to Crohn’s disease, regardless of how the cells were stimulated. Meanwhile, in the inflamed intestinal tissue itself, a related chemokine called GCP-2 (CXCL6), which also binds CXCR1, was highly expressed on blood vessel walls at sites of ulceration. This selective expression of GCP-2 but not CXCL8 at these sites suggests GCP-2 plays a distinct role in the intestinal inflammation of IBD.¹⁵

Genetic Variants in CXCR1 and Urinary Tract Infections

Because CXCR1 helps neutrophils reach infection sites, researchers have hypothesized that people carrying certain genetic variants in the CXCR1 gene might be more susceptible to infections, particularly urinary tract infections (UTIs), where neutrophil recruitment into the urinary tract is a critical defense. The evidence here is mixed and appears to depend heavily on which population is studied.

A pooled analysis of data from over 4,000 subjects found that one CXCR1 variant (rs2234671) was associated with roughly double the risk of UTI in children, with an even stronger association in pediatric patients with acute pyelonephritis, where the odds were about two and a half times higher.¹⁶ However, the same variant showed no significant link to UTI in adult women with recurrent infections.¹⁷ And in a study of adults with type 2 diabetes in North India, no association was found between this CXCR1 polymorphism and UTI susceptibility either.¹⁸ The pediatric link may reflect the outsized importance of innate immune defenses in children, whose adaptive immune systems are still maturing and who are more reliant on neutrophil-driven clearance of bacteria from the urinary tract.

Drugs That Target CXCR1

Over the past two decades, multiple approaches to blocking CXCR1 have been developed: small-molecule inhibitors, antibodies against CXCL8, and antibodies against the receptor itself.¹⁹ The clinical results so far show both promise and sobering failures.

Reparixin, a small-molecule inhibitor of CXCR1 and CXCR2, was tested in a window-of-opportunity trial in early-stage breast cancer. Among 17 patients with paired biopsies, some showed reductions in cancer stem cell markers after treatment.²⁰ But in a larger randomized trial for metastatic triple-negative breast cancer, adding reparixin to chemotherapy did not improve progression-free survival compared with chemotherapy alone: the median was about 5.5 months in both groups.²¹ That trial was a significant disappointment and raised questions about whether blocking CXCR1/2 alone is enough to make a meaningful difference once cancer has already spread widely.

A newer agent, SX-682, takes a different approach. It is an oral allosteric inhibitor of CXCR1 and CXCR2 designed to be combined with immunotherapy rather than chemotherapy. In a dose-escalation trial combining SX-682 with the checkpoint inhibitor pembrolizumab in patients with metastatic melanoma who had already progressed on anti-PD-1 therapy, the response rate at the highest dose tested was 21 percent, and the disease control rate was 63 percent. Importantly, the disease control rate was clearly dose-dependent, rising from 0 percent at the lowest doses to 63 percent at 200 mg.²² These early results suggest that pairing CXCR1/2 blockade with immunotherapy may be a more productive strategy than combining it with traditional chemotherapy, likely because the receptor blockade helps remove the immunosuppressive shield around the tumor at the same time the checkpoint inhibitor releases the T-cell brake.

The Safety Trade-Off in Blocking a Frontline Immune Receptor

CXCR1 is not an incidental player in host defense. It is one of the primary receptors that neutrophils use to find and kill invading bacteria. Blocking it to control inflammation or cancer inevitably raises the question of whether you are leaving the patient vulnerable to infection. This concern is particularly acute in conditions like sepsis or ARDS, where the same neutrophil-driven inflammation causing tissue damage is also the body’s attempt to fight off the infection that triggered the crisis in the first place.²³

The drugs developed so far have generally shown tolerable safety profiles in clinical trials, but those trials enrolled cancer patients receiving other immunosuppressive treatments, making it harder to isolate CXCR1 blockade’s specific effect on infection risk. Moving these therapies into settings where infection control is the primary concern, such as ARDS during bacterial pneumonia, will require careful dose-finding to identify a window where neutrophil-mediated tissue damage is reduced without crippling the antimicrobial response. Animal knockout studies show proof of concept: removing CXCR1 protects against lung injury.¹⁴ Whether partial pharmacological blockade can replicate that protection in humans without unacceptable infection risk is the key unanswered question that will shape the next phase of CXCR1-targeted therapy development.